|
CA2738566C
(en)
*
|
2008-10-01 |
2024-04-30 |
Micromet Ag |
Bispecific single chain antibodies with specificity for high molecular weight target antigens
|
|
WO2010037835A2
(en)
*
|
2008-10-01 |
2010-04-08 |
Micromet Ag |
Cross-species-specific pscaxcd3, cd19xcd3, c-metxcd3, endosialinxcd3, epcamxc d3, igf-1rxcd3 or fapalpha xcd3 bispecific single chain antibody
|
|
US10981998B2
(en)
*
|
2008-10-01 |
2021-04-20 |
Amgen Research (Munich) Gmbh |
Cross-species-specific single domain bispecific single chain antibody
|
|
HUE030090T2
(en)
|
2008-10-01 |
2017-04-28 |
Amgen Res Munich Gmbh |
Cross-species-specific psmaxcd3 bispecific single chain antibody
|
|
TWI736437B
(zh)
|
2010-11-30 |
2021-08-11 |
日商中外製藥股份有限公司 |
細胞傷害誘導治療劑
|
|
JP2014518615A
(ja)
|
2011-04-22 |
2014-08-07 |
エマージェント プロダクト デベロップメント シアトル, エルエルシー |
前立腺特異的膜抗原結合タンパク質および関連組成物ならびに方法
|
|
MX369220B
(es)
*
|
2011-05-21 |
2019-10-31 |
Macrogenics Inc |
Moleculas que enlazan cd3 capaces de enlazar a cd3 humano y no humano.
|
|
US12466897B2
(en)
|
2011-10-10 |
2025-11-11 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
|
US10968276B2
(en)
|
2013-03-12 |
2021-04-06 |
Xencor, Inc. |
Optimized anti-CD3 variable regions
|
|
US9605084B2
(en)
|
2013-03-15 |
2017-03-28 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US11053316B2
(en)
|
2013-01-14 |
2021-07-06 |
Xencor, Inc. |
Optimized antibody variable regions
|
|
DK2943511T3
(da)
*
|
2013-01-14 |
2019-10-21 |
Xencor Inc |
Nye heterodimeriske proteiner
|
|
GB201303308D0
(en)
*
|
2013-02-25 |
2013-04-10 |
Oxford Biotherapeutics Ltd |
Therapeutic and diagnostic target
|
|
US10858417B2
(en)
|
2013-03-15 |
2020-12-08 |
Xencor, Inc. |
Heterodimeric proteins
|
|
AU2014286116A1
(en)
|
2013-07-05 |
2016-02-04 |
Genmab A/S |
Humanized or chimeric CD3 antibodies
|
|
EP3406633B1
(en)
|
2013-07-25 |
2022-03-02 |
Cytomx Therapeutics Inc. |
Multispecific antibodies, multispecific activatable antibodies and methods of using the same
|
|
CA3131724A1
(en)
|
2013-12-17 |
2015-06-25 |
Genentech, Inc. |
Anti-cd3 antibodies and methods of use
|
|
SI3122781T1
(sl)
|
2014-03-28 |
2020-03-31 |
Xencor, Inc. |
Bispecifična protitelesa, ki se vežejo na CD38 in CD3
|
|
MX380176B
(es)
|
2014-04-07 |
2025-03-12 |
Chugai Pharmaceutical Co Ltd |
Molecula ligada a antigeno inmunoactivada.
|
|
MX2016014434A
(es)
|
2014-05-13 |
2017-02-23 |
Chugai Pharmaceutical Co Ltd |
Molecula de union a antigeno redirigida a celulas t para celulas que tienen funcion de inmunosupresion.
|
|
RU2016151645A
(ru)
|
2014-07-01 |
2018-08-03 |
Пфайзер Инк. |
Биспецифические гетеродимерные диантитела и их применение
|
|
US9212225B1
(en)
|
2014-07-01 |
2015-12-15 |
Amphivena Therapeutics, Inc. |
Bispecific CD33 and CD3 binding proteins
|
|
AU2015292406B2
(en)
|
2014-07-25 |
2021-03-11 |
Cytomx Therapeutics, Inc |
Anti-CD3 antibodies, activatable anti-CD3 antibodies, multispecific anti-CD3 antibodies, multispecific activatable anti-CD3 antibodies, and methods of using the same
|
|
EP3174901B1
(en)
|
2014-07-31 |
2019-06-26 |
Amgen Research (Munich) GmbH |
Optimized cross-species specific bispecific single chain antibody constructs
|
|
EP2982693A1
(en)
|
2014-08-07 |
2016-02-10 |
Affimed Therapeutics AG |
CD3 binding domain
|
|
SG11201700901SA
(en)
|
2014-08-08 |
2017-03-30 |
Alector Llc |
Anti-trem2 antibodies and methods of use thereof
|
|
HUE055115T2
(hu)
|
2014-11-26 |
2021-10-28 |
Xencor Inc |
CD3-at és CD20-at kötõ heterodimer antitestek
|
|
EA037065B1
(ru)
|
2014-11-26 |
2021-02-01 |
Ксенкор, Инк. |
Гетеродимерные антитела, связывающие cd3 и cd38
|
|
US10259887B2
(en)
|
2014-11-26 |
2019-04-16 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and tumor antigens
|
|
CN107709363A
(zh)
*
|
2015-05-01 |
2018-02-16 |
基因泰克公司 |
掩蔽抗cd3抗体和使用方法
|
|
MA42059A
(fr)
*
|
2015-05-06 |
2018-03-14 |
Janssen Biotech Inc |
Agents de liaison bispécifique à l'antigène membranaire spécifique de la prostate (psma) et utilisations de ceux-ci
|
|
EP3296395B2
(en)
|
2015-05-13 |
2024-06-19 |
Chugai Seiyaku Kabushiki Kaisha |
Multiple antigen binding molecular fusion, pharmaceutical composition, method for identifying linear epitope, and method for preparing multiple antigen binding molecular fusion
|
|
WO2016196230A1
(en)
|
2015-05-29 |
2016-12-08 |
Amphivena Therapeutics, Inc. |
Methods of using bispecific cd33 and cd3 binding proteins
|
|
TWI744242B
(zh)
|
2015-07-31 |
2021-11-01 |
德商安美基研究(慕尼黑)公司 |
Egfrviii及cd3抗體構築體
|
|
TWI796283B
(zh)
|
2015-07-31 |
2023-03-21 |
德商安美基研究(慕尼黑)公司 |
Msln及cd3抗體構築體
|
|
JOP20160154B1
(ar)
*
|
2015-07-31 |
2021-08-17 |
Regeneron Pharma |
أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها
|
|
TWI829617B
(zh)
|
2015-07-31 |
2024-01-21 |
德商安美基研究(慕尼黑)公司 |
Flt3及cd3抗體構築體
|
|
EA039859B1
(ru)
|
2015-07-31 |
2022-03-21 |
Эмджен Рисерч (Мюник) Гмбх |
Биспецифические конструкты антител, связывающие egfrviii и cd3
|
|
IL319047A
(en)
*
|
2015-08-28 |
2025-04-01 |
Amunix Operating Inc |
Chimeric polypeptide composition and methods for its preparation and use
|
|
WO2017053469A2
(en)
|
2015-09-21 |
2017-03-30 |
Aptevo Research And Development Llc |
Cd3 binding polypeptides
|
|
WO2017086419A1
(ja)
|
2015-11-18 |
2017-05-26 |
中外製薬株式会社 |
液性免疫応答の増強方法
|
|
JP6931329B2
(ja)
|
2015-11-18 |
2021-09-01 |
中外製薬株式会社 |
免疫抑制機能を有する細胞に対するt細胞リダイレクト抗原結合分子を用いた併用療法
|
|
CA3007030A1
(en)
*
|
2015-12-07 |
2017-06-15 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and psma
|
|
WO2017134158A1
(en)
*
|
2016-02-03 |
2017-08-10 |
Amgen Research (Munich) Gmbh |
Psma and cd3 bispecific t cell engaging antibody constructs
|
|
EP3442567B1
(en)
*
|
2016-04-13 |
2025-12-03 |
Orimabs Ltd. |
Anti-psma antibodies and use thereof
|
|
EP4257613A3
(en)
|
2016-06-14 |
2023-12-13 |
Xencor, Inc. |
Bispecific checkpoint inhibitor antibodies
|
|
KR20230129583A
(ko)
|
2016-06-21 |
2023-09-08 |
테네오바이오, 인코포레이티드 |
Cd3 결합 항체
|
|
AU2017290086A1
(en)
|
2016-06-28 |
2019-01-24 |
Xencor, Inc. |
Heterodimeric antibodies that bind somatostatin receptor 2
|
|
EP4050034B1
(en)
|
2016-09-14 |
2024-05-08 |
TeneoOne, Inc. |
Cd3 binding antibodies
|
|
ES2833254T3
(es)
|
2016-09-15 |
2021-06-14 |
Novimmune Sa |
Presentación de anticuerpos biespecíficos sobre la superficie de fagos
|
|
CA3037380A1
(en)
*
|
2016-10-11 |
2018-04-19 |
Agenus Inc. |
Anti-lag-3 antibodies and methods of use thereof
|
|
KR20190074300A
(ko)
|
2016-11-15 |
2019-06-27 |
제넨테크, 인크. |
항-cd20/항-cd3 이중특이적 항체에 의한 치료를 위한 투약
|
|
KR102633423B1
(ko)
|
2016-12-21 |
2024-02-06 |
테네오바이오, 인코포레이티드 |
항-bcma 중쇄-단독 항체
|
|
KR20240023449A
(ko)
|
2017-02-08 |
2024-02-21 |
드래곤플라이 쎄라퓨틱스, 인크. |
천연 킬러 세포의 활성화를 위한 다중-특이적 결합 단백질 및 암 치료에서의 그의 치료적 용도
|
|
JP7685821B2
(ja)
|
2017-02-20 |
2025-05-30 |
ドラゴンフライ セラピューティクス, インコーポレイテッド |
Her2、NKG2DおよびCD16に結合するタンパク質
|
|
WO2018177371A1
(en)
*
|
2017-03-29 |
2018-10-04 |
Taipei Medical University |
Antigen-specific t cells and uses thereof
|
|
CA3067584A1
(en)
|
2017-06-20 |
2018-12-27 |
Teneobio, Inc. |
Anti-bcma heavy chain-only antibodies
|
|
US11427642B2
(en)
|
2017-06-20 |
2022-08-30 |
Teneoone, Inc. |
Anti-BCMA heavy chain-only antibodies
|
|
IL270235B2
(en)
*
|
2017-08-03 |
2025-02-01 |
Alector Llc |
Anti-TREM2 antibodies and methods of using them
|
|
IL273937B1
(en)
|
2017-10-14 |
2025-08-01 |
Cytomx Therapeutics Inc |
Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof
|
|
US10981992B2
(en)
|
2017-11-08 |
2021-04-20 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
|
KR20200085828A
(ko)
|
2017-11-08 |
2020-07-15 |
젠코어 인코포레이티드 |
신규의 항-pd-1 서열을 사용한 이중특이적 및 단일특이적 항체
|
|
MA51291A
(fr)
|
2017-12-19 |
2020-10-28 |
Xencor Inc |
Protéines de fusion il-2 fc modifiées
|
|
EP3728319A1
(en)
|
2017-12-22 |
2020-10-28 |
TeneoBio, Inc. |
Heavy chain antibodies binding to cd22
|
|
TW201940518A
(zh)
|
2017-12-29 |
2019-10-16 |
美商安進公司 |
針對muc17和cd3之雙特異性抗體構建體
|
|
PT3749346T
(pt)
|
2018-02-08 |
2024-09-05 |
Dragonfly Therapeutics Inc |
Combinações de domínios variáveis de anticorpos dirigidas ao receptor nkg2d
|
|
KR20200118065A
(ko)
|
2018-02-08 |
2020-10-14 |
제넨테크, 인크. |
이중특이적 항원-결합 분자 및 이의 사용 방법
|
|
KR20200118824A
(ko)
|
2018-02-08 |
2020-10-16 |
드래곤플라이 쎄라퓨틱스, 인크. |
자연 살해 세포를 활성화시키는 다중-특이성 결합 단백질을 수반하는 암의 병용 요법
|
|
CA3091424A1
(en)
|
2018-02-20 |
2019-08-29 |
Dragonfly Therapeutics, Inc. |
Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of use
|
|
WO2019175658A1
(en)
|
2018-03-14 |
2019-09-19 |
Novimmune Sa |
Anti-cd3 epsilon antibodies and methods of use thereof
|
|
CN112469477A
(zh)
|
2018-04-04 |
2021-03-09 |
Xencor股份有限公司 |
与成纤维细胞活化蛋白结合的异源二聚体抗体
|
|
WO2019204655A1
(en)
|
2018-04-18 |
2019-10-24 |
Xencor, Inc. |
Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains
|
|
AU2019256539A1
(en)
|
2018-04-18 |
2020-11-26 |
Xencor, Inc. |
PD-1 targeted heterodimeric fusion proteins containing IL-15/IL-15Ra Fc-fusion proteins and PD-1 antigen binding domains and uses thereof
|
|
WO2020025564A1
(en)
|
2018-07-31 |
2020-02-06 |
Heidelberg Pharma Research Gmbh |
Humanized antibodies against psma
|
|
EP3833392A4
(en)
|
2018-08-08 |
2022-05-18 |
Dragonfly Therapeutics, Inc. |
Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use
|
|
SG11202101298XA
(en)
|
2018-08-08 |
2021-03-30 |
Dragonfly Therapeutics Inc |
Proteins binding nkg2d, cd16 and a tumor-associated antigen
|
|
EA202091888A1
(ru)
|
2018-08-08 |
2020-10-23 |
Драгонфлай Терапьютикс, Инк. |
Вариабельные домены антител, нацеленные на рецептор nkg2d
|
|
AU2019355971B2
(en)
|
2018-10-03 |
2025-05-08 |
Xencor, Inc. |
IL-12 heterodimeric Fc-fusion proteins
|
|
BR112021016955A2
(pt)
|
2019-03-01 |
2021-11-23 |
Xencor Inc |
Composição, composição de ácido nucleico, composição de vetor de expressão, vetor de expressão, célula hospedeira, métodos de produção de um domínio de ligação de membro de família 3 de pirofosfatase/fosfodiesterase de ectonucleotídeo e de tratamento de um câncer, anticorpo anti-enpp3, e, anticorpo heterodimérico
|
|
KR20210149076A
(ko)
|
2019-04-05 |
2021-12-08 |
테네오바이오, 인코포레이티드 |
Psma에 결합하는 중쇄 항체
|
|
CN112390884B
(zh)
*
|
2019-04-09 |
2022-07-08 |
苏州大学 |
Semaphorin7A单克隆抗体及其在制备用于治疗炎症疾病药物方面的应用
|
|
BR112021024956A2
(pt)
|
2019-06-14 |
2022-01-25 |
Teneobio Inc |
Anticorpos multiespecíficos de cadeia pesada que se ligam a cd22 e cd3
|
|
WO2021004400A1
(zh)
*
|
2019-07-06 |
2021-01-14 |
苏州克睿基因生物科技有限公司 |
一种表达cd3抗体受体复合物的免疫细胞及其用途
|
|
US20230374130A1
(en)
*
|
2019-07-30 |
2023-11-23 |
Qlsf Biotherapeutics, Inc. |
Bispecific anti lrrc15 and cd3epsilon antibodies
|
|
CR20220330A
(es)
|
2019-12-13 |
2022-08-04 |
Genentech Inc |
Anticuerpos anti-ly6g6d y métodos de uso.
|
|
AU2021207470A1
(en)
|
2020-01-13 |
2022-07-07 |
Aptevo Research And Development Llc |
Formulations for protein therapeutics
|
|
BR112022013730A2
(pt)
|
2020-01-13 |
2022-10-11 |
Aptevo Res & Development Llc |
Métodos e composições para prevenir a adsorção de proteínas terapêuticas aos componentes do sistema de distribuição de drogas
|
|
CA3177024A1
(en)
|
2020-05-06 |
2021-11-11 |
Dragonfly Therapeutics, Inc. |
Proteins binding nkg2d, cd16 and clec12a
|
|
US11919956B2
(en)
|
2020-05-14 |
2024-03-05 |
Xencor, Inc. |
Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
|
|
EP4200332A1
(en)
|
2020-08-19 |
2023-06-28 |
Xencor, Inc. |
Anti-cd28 and/or anti-b7h3 compositions
|
|
TWI874719B
(zh)
|
2020-11-04 |
2025-03-01 |
美商建南德克公司 |
用抗cd20/抗cd3雙特異性抗體進行治療之給藥
|
|
CN116323671A
(zh)
|
2020-11-06 |
2023-06-23 |
安进公司 |
具有增加的选择性的多靶向性双特异性抗原结合分子
|
|
AU2021396172A1
(en)
*
|
2020-12-09 |
2023-07-06 |
Janux Therapeutics, Inc. |
Compositions and methods related to tumor activated antibodies targeting psma and effector cell antigens
|
|
EP4259202A4
(en)
*
|
2020-12-09 |
2025-01-15 |
Janux Therapeutics, Inc. |
COMPOSITIONS AND METHODS RELATED TO TUMOR-ACTIVATED ANTIBODIES AGAINST TROP2 AND EFFECTOR CELL ANTIGENS
|
|
WO2022187539A1
(en)
|
2021-03-03 |
2022-09-09 |
Dragonfly Therapeutics, Inc. |
Methods of treating cancer using multi-specific binding proteins that bind nkg2d, cd16 and a tumor-associated antigen
|
|
MX2023010499A
(es)
|
2021-03-09 |
2023-09-18 |
Xencor Inc |
Anticuerpos heterodimericos que se unen a cd3 y cldn6.
|
|
JP2024509274A
(ja)
|
2021-03-10 |
2024-02-29 |
ゼンコア インコーポレイテッド |
Cd3及びgpc3に結合するヘテロ二量体抗体
|
|
CA3213632A1
(en)
|
2021-04-30 |
2022-11-03 |
F. Hoffmann-La Roche Ag |
Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate
|
|
CA3217180A1
(en)
|
2021-05-06 |
2022-11-10 |
Amgen Research (Munich) Gmbh |
Cd20 and cd22 targeting antigen-binding molecules for use in proliferative diseases
|
|
US12291575B2
(en)
|
2021-05-14 |
2025-05-06 |
Genentech, Inc. |
Methods for treatment of CD20-positive proliferative disorder with mosunetuzumab and polatuzumab vedotin
|
|
CA3219832A1
(en)
|
2021-05-21 |
2022-11-24 |
Fatih Uckun |
Dosing regimens for protein therapeutics
|
|
JP2025509892A
(ja)
|
2022-03-21 |
2025-04-11 |
アムジェン インコーポレイテッド |
前立腺癌の治療のためのt細胞エンゲージ分子を用いた併用療法
|
|
IL316597A
(en)
|
2022-05-12 |
2024-12-01 |
Amgen Res Munich Gmbh |
Multi-chain, multi-purpose, bispecific antigen-binding compounds with enhanced sensitivity
|